Berry Leslie R, Klement Petr, Andrew Maureen, Chan Anthony K C
Henderson Research Centre, Hamilton, Canada.
Am J Respir Cell Mol Biol. 2003 Feb;28(2):150-8. doi: 10.1165/rcmb.4849.
Extravascular coagulation within the lung airspace is a hallmark of respiratory distress syndrome (RDS) in premature infants. We previously showed that covalent antithrombin-heparin complex (ATH) is superior to noncovalent antithrombin (AT) + heparin (H) mixtures at inhibiting plasma thrombin generation on rat fetal distal lung epithelium (FDLE) in vitro. However, heparin cofactor II (HC) has been shown to selectively inhibit thrombin, which may be advantageous if other enzyme activities are present in the airspace. We compared the abilities of ATH, covalent HC-heparin complex (HCH), and covalent HC-dermatan sulfate (HCD) to inhibit thrombin generation on FDLE in plasmas from either adults or newborns. In the presence of ATH, peak free thrombin generation in adult plasma on the cell surface was reduced by 92% compared with controls (no anticoagulant). However, whereas HCH reduced peak free thrombin generation in adult plasma by 81%, HCD was only able to reduce activity by 33%. All covalent complexes caused a greater decrease in thrombin activity compared with that with the corresponding noncovalent serpin + heparinoid mixtures. Experiments in plasma from newborns resulted in peak free thrombin that was less than or equal to that in adult plasma when covalent conjugates were added. Relative peak free thrombin was proportional to rate of prothrombin consumption and amount of thrombin-inhibitor complexes formed. In vivo, experiments in newborn rats showed that a greater percentage of intratracheally instilled ATH and HCH could be recovered in lung lavage fluid compared withwith that for HCD. In summary, ATH, HCH, and HCD are inhibitors of thrombin generation on FDLE superior to the corresponding noncovalent mixtures, with ATH and HCH being more potent than HCD. Covalent conjugates of AT or HC with H may be preferred in treatment of extravascular coagulation.
肺气腔内的血管外凝血是早产儿呼吸窘迫综合征(RDS)的一个标志。我们之前表明,共价抗凝血酶-肝素复合物(ATH)在体外抑制大鼠胎儿远端肺上皮(FDLE)上的血浆凝血酶生成方面优于非共价抗凝血酶(AT)+肝素(H)混合物。然而,已证明肝素辅因子II(HC)可选择性抑制凝血酶,如果气腔内存在其他酶活性,这可能具有优势。我们比较了ATH、共价HC-肝素复合物(HCH)和共价HC-硫酸皮肤素(HCD)在成人或新生儿血浆中抑制FDLE上凝血酶生成的能力。在存在ATH的情况下,与对照组(无抗凝剂)相比,成人血浆中细胞表面的游离凝血酶生成峰值降低了92%。然而,虽然HCH使成人血浆中的游离凝血酶生成峰值降低了81%,但HCD仅能将活性降低33%。与相应的非共价丝氨酸蛋白酶抑制剂+类肝素混合物相比,所有共价复合物导致的凝血酶活性下降幅度更大。在添加共价缀合物时,新生儿血浆实验产生的游离凝血酶峰值小于或等于成人血浆中的峰值。相对游离凝血酶峰值与凝血酶原消耗速率和形成的凝血酶-抑制剂复合物量成正比。在体内,新生大鼠实验表明,与HCD相比,气管内注入的ATH和HCH在肺灌洗液中的回收率更高。总之,ATH、HCH和HCD是FDLE上凝血酶生成的抑制剂,优于相应的非共价混合物,ATH和HCH比HCD更有效。AT或HC与H的共价缀合物在治疗血管外凝血方面可能更受青睐。